Hims & Hers Health to Sell Wegovy, Ozempic, Launch Weight-Loss Membership

Dow Jones03-27 00:23

By Katherine Hamilton

Hims & Hers Health will be selling some of Novo Nordisk's GLP-1 medications, including Wegovy.

Starting Thursday, eligible customers can access Wegovy pills and injections in several different dosage amounts. Ozempic injection pens, which are approved for treating diabetes but not obesity, also will be available.

Prices start as low as $149 a month, Hims & Hers said.

The health platform also is introducing a new membership specifically for weight loss. The membership will include support services, 24/7 direct access to providers, personalized nutrition guidance, ongoing clinical check-ins and peer support.

Membership starts at $39 for the first month and $149 each month after.

Medication costs are separate and may be covered under the customers' HSA and FSA plan.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

March 26, 2026 12:23 ET (16:23 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622715862?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 00:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622715862","market":"sg","top_or_hot":-1,"title":"Hims & Hers Health to Sell Wegovy, Ozempic, Launch Weight-Loss Membership","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Hims &amp; Hers Health will be selling some of <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s GLP-1 medications, including Wegovy. \n</p>\n<p>\n  Starting Thursday, eligible customers can access Wegovy pills and injections in several different dosage amounts. Ozempic injection pens, which are approved for treating diabetes but not obesity, also will be available. \n</p>\n<p>\n  Prices start as low as $149 a month, Hims &amp; Hers said. \n</p>\n<p>\n  The health platform also is introducing a new membership specifically for weight loss. The membership will include support services, 24/7 direct access to providers, personalized nutrition guidance, ongoing clinical check-ins and peer support. \n</p>\n<p>\n  Membership starts at $39 for the first month and $149 each month after. \n</p>\n<p>\n  Medication costs are separate and may be covered under the customers' HSA and FSA plan. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 26, 2026 12:23 ET (16:23 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hims & Hers Health to Sell Wegovy, Ozempic, Launch Weight-Loss Membership</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHims & Hers Health to Sell Wegovy, Ozempic, Launch Weight-Loss Membership\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-27 00:23</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Hims &amp; Hers Health will be selling some of <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s GLP-1 medications, including Wegovy. \n</p>\n<p>\n  Starting Thursday, eligible customers can access Wegovy pills and injections in several different dosage amounts. Ozempic injection pens, which are approved for treating diabetes but not obesity, also will be available. \n</p>\n<p>\n  Prices start as low as $149 a month, Hims &amp; Hers said. \n</p>\n<p>\n  The health platform also is introducing a new membership specifically for weight loss. The membership will include support services, 24/7 direct access to providers, personalized nutrition guidance, ongoing clinical check-ins and peer support. \n</p>\n<p>\n  Membership starts at $39 for the first month and $149 each month after. \n</p>\n<p>\n  Medication costs are separate and may be covered under the customers' HSA and FSA plan. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 26, 2026 12:23 ET (16:23 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1093756168.USD","symbol_name":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2622715862","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622715862","pubTimestamp":1774542180,"columns":[{"name":"Product Release","id":31,"label_key":"productRelease"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Hims & Hers Health will be selling some of Novo Nordisk's GLP-1 medications, including Wegovy.Starting Thursday, eligible customers can access Wegovy pills and injections in several different dosage amounts. Ozempic injection pens, which are approved for treating diabetes but not obesity, also will be available.Prices start as low as $149 a month, Hims & Hers said.The health platform also is introducing a new membership specifically for weight loss. The membership will include support services, 24/7 direct access to providers, personalized nutrition guidance, ongoing clinical check-ins and peer support.Membership starts at $39 for the first month and $149 each month after.Medication costs are separate and may be covered under the customers' HSA and FSA plan.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","HIYY":"YieldMax HIMS Option Income Strategy ETF","BK4007":"制药","BK4532":"文艺复兴科技持仓","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","HIMY":"Defiance Leveraged Long + Income HIMS ETF","NVOX":"2倍做多NVO ETF-Defiance","NVOH":"Novo Nordisk A/S B Shares ADRhedged","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","HIMZ":"DEFIANCE DAILY TARGET 2X LONG HIMS ETF","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4196":"保健护理服务","HIMS":"Hims & Hers Health Inc.","BK4588":"碎股","BK4599":"减肥药","HMYY":"GraniteShares YieldBoost HIMS ETF"},"translate_title":"Hims&Hers Health将出售Wegovy、Ozempic并推出减肥会员","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMY":0.6,"HMYY":0.6,"NVOX":0.6,"HIYY":0.6,"NVOH":0.6,"HIMZ":0.6,"HIMS":1.96},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Hims & Hers Health will be selling some of Novo Nordisk's GLP-1 medications, including Wegovy. \n\n\n  Starting Thursday, eligible customers can access Wegovy pills and injections in several different dosage amounts. Ozempic injection pens, which are approved for treating diabetes but not obesity, also will be available. \n\n\n  Prices start as low as $149 a month, Hims & Hers said. \n\n\n  The health platform also is introducing a new membership specifically for weight loss. The membership will include support services, 24/7 direct access to providers, personalized nutrition guidance, ongoing clinical check-ins and peer support. \n\n\n  Membership starts at $39 for the first month and $149 each month after. \n\n\n  Medication costs are separate and may be covered under the customers' HSA and FSA plan. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 26, 2026 12:23 ET (16:23 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622715862","isCrawlerRequest":true}